ACELYRIN，Inc.宣佈在歐洲風溼病學會2024的晚期口頭報告中分享其在銀屑病性關節

快訊 · 06/05 19:00

ACELYRIN, Inc. Announces Positive 16-Week Data From Its Global Phase 2B/3 Trial of Izokibep in Psoriatic Arthritis to Be Shared During Late-Breaking Oral Presentation at Eular 2024

ACELYRIN，Inc.宣佈在歐洲風溼病學會2024的晚期口頭報告中分享其在銀屑病性關節炎的全球2B/3期試驗中的16周積極數據